Chao Liu

Dr. Chao Liu


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 November 2008 in Nature Biotechnology
Verified
Journal Article
Open access
PDF file
RFRong Fan
Rong Fan
OVOphir Vermesh
Ophir Vermesh
ASAlok Srivastava
Alok Srivastava
BYBrian K H Yen
Brian K H Yen
LQLidong Qin
Lidong Qin
JHJames R Heath
James R Heath
Fan et al. describe a microfluidic chip for multiplexed analysis of proteins in a finger prick of blood. The chip separates plasma from diluted whole blood and quantifies panels of serum proteins in about 10 minutes, minimizing protein degradation. As the tissue that contains the largest representation of the human proteome1, blood is the most important fluid for clinical diagnostics2,3,4. However, although changes of plasma protein profiles reflect physiological or pathological conditions associated with many human diseases, only a handful of plasma proteins are routinely used in clinical tests. Reasons for this include the intrinsic complexity of the plasma proteome1, the heterogeneity of human diseases and the rapid degradation of proteins in sampled blood5. We report an integrated microfluidic system, the integrated blood barcode chip that can sensitively sample a large panel of protein biomarkers over broad concentration ranges and within 10 min of sample collection. It enables on-chip blood separation and rapid measurement of a panel of plasma proteins from quantities of whole blood as small as those obtained by a finger prick. Our device holds potential for inexpensive, noninvasive and informative clinical diagnoses, particularly in point-of-care settings.

22 May 2011 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
CMChao Ma
Chao Ma
RFRong Fan
Rong Fan
HAHabib Ahmad
Habib Ahmad
QSQihui Shi
Qihui Shi
BCBegonya Comin-Anduix
Begonya Comin-Anduix
JHJames R Heath
James R Heath

10 December 2018 in Nature
Verified
Journal Article
Closed access
PDF file
AWAlex W. Wilkinson
Alex W. Wilkinson
JDJonathan Diep
Jonathan Diep
SDShaobo Dai
Shaobo Dai
SLShuo Liu
Shuo Liu
YOYaw Shin Ooi
Yaw Shin Ooi
OGOr Gozani
Or Gozani

1 January 2016 in Journal of Experimental Biology
Verified
Journal Article
Open access
PDF file
JSJames A. Spudich
James A. Spudich
TATural Aksel
Tural Aksel
SBSadie R. Bartholomew
Sadie R. Bartholomew
SNSuman Nag
Suman Nag
MKMasataka Kawana
Masataka Kawana
KRKathleen M. Ruppel
Kathleen M. Ruppel
Hypertrophic cardiomyopathy is the most frequently occurring inherited cardiovascular disease, with a prevalence of more than one in 500 individuals worldwide. Genetically acquired dilated cardiomyopathy is a related disease that is less prevalent. Both are caused by mutations in the genes encoding the fundamental force-generating protein machinery of the cardiac muscle sarcomere, including human β-cardiac myosin, the motor protein that powers ventricular contraction. Despite numerous studies, most performed with non-human or non-cardiac myosin, there is no clear consensus about the mechanism of action of these mutations on the function of human β-cardiac myosin. We are using a recombinantly expressed human β-cardiac myosin motor domain along with conventional and new methodologies to characterize the forces and velocities of the mutant myosins compared with wild type. Our studies are extending beyond myosin interactions with pure actin filaments to include the interaction of myosin with regulated actin filaments containing tropomyosin and troponin, the roles of regulatory light chain phosphorylation on the functions of the system, and the possible roles of myosin binding protein-C and titin, important regulatory components of both cardiac and skeletal muscles.

1 December 2016 in Cell Reports
Verified
Journal Article
Open access
AAArjun S. Adhikari
Arjun S. Adhikari
KKKristina B. Kooiker
Kristina B. Kooiker
SSSaswata S. Sarkar
Saswata S. Sarkar
CLChao Liu
Chao Liu
DBDaniel Bernstein
Daniel Bernstein
KRKathleen M. Ruppel
Kathleen M. Ruppel
Hypertrophic cardiomyopathy (HCM) is a heritable cardiovascular disorder that affects 1 in 500 people. A significant percentage of HCM is attributed to mutations in β-cardiac myosin, the motor protein that powers ventricular contraction. This study reports how two early-onset HCM mutations, D239N and H251N, affect the molecular biomechanics of human β-cardiac myosin. We observed significant increases (20%-90%) in actin gliding velocity, intrinsic force, and ATPase activity in comparison to wild-type myosin. Moreover, for H251N, we found significantly lower binding affinity between the S1 and S2 domains of myosin, suggesting that this mutation may further increase hyper-contractility by releasing active motors. Unlike previous HCM mutations studied at the molecular level using human β-cardiac myosin, early-onset HCM mutations lead to significantly larger changes in the fundamental biomechanical parameters and show clear hyper-contractility.

11 June 2021 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
ARAlison Schroer Vander Roest
Alison Schroer Vander Roest
CLChao Liu
Chao Liu
MMMakenna M. Morck
Makenna M. Morck
KKKristina Bezold Kooiker
Kristina Bezold Kooiker
GJGwanghyun Jung
Gwanghyun Jung
DBDaniel Bernstein
Daniel Bernstein
Significance: Heart disease is the leading cause of death worldwide, and hypertrophic cardiomyopathy (HCM) is the most common inherited form of heart disease, affecting over 1 in 200 people. Mutations in myosin, the motor protein responsible for contraction of the heart, are a common cause of HCM but have diverse effects on the biomechanics of the myosin protein. We demonstrate that complex biomechanical effects of mutations associated with heart disease can be effectively studied and understood using a multiscale experimental and computational modeling approach. This work confirms an important role for disruption of the super relaxed state for one particular HCM mutation and provides an approach that can be extended to aid in the understanding of disease mechanisms for different mutations.